Adding GLP-1 RA:Data for the use of GLP-1 RA in T2D with severe renal failure (< 30 mL/min/1.73 m2) are derived from subsets of more extensive trials that included a minimal number of patients, such as 2.5% in LEADER RENAL [121] (liraglutide), 2.5% in SUSTAIN-6 [78] (injectable semaglutide), and 1% in REWIND RENAL [111] (dulaglutide). This evidence concerns the gene GLP1R and Renal insufficiency.